Polarean Imaging plc (AIM:POLX)

Market Cap	4.83M
Revenue (ttm)	1.87M
Net Income (ttm)	-7.00M
Shares Out	1.21B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,390,931
Average Volume	11,851,174
Open	0.3810
Previous Close	0.4000
Day's Range	0.3650 - 0.4090
52-Week Range	0.3500 - 1.7000
Beta	-0.09
RSI	31.45
Earnings Date	Dec 24, 2025

About Polarean Imaging

Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; chest...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Employees: 26
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: POLX

Financial Performance

In 2024, Polarean Imaging's revenue was $3.09 million, an increase of 246.82% compared to the previous year's $890,933. Losses were -$8.54 million, -28.14% less than in 2023.

Financial numbers in USD